Resolution Therapeutics doses first patient in phase I/II Emerald study of RTX001 for end-stage liver disease
RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options
RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options
Under the partnership, the Pfizer INDovation program will empower DPIIT-recognized startups with grants of up to Rs. 60 lakhs each, along with a tailored 18-month incubation program delivered by Social Alpha
The U.S. FDA issued a Form 483 with five observations
The medicine was well tolerated, with no unexpected safety issue
Now integrates with Abbott’s instinct sensor and approved for type 2 diabetes
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
Phase 1 has a total reactor capacity of 440 kL with 63 reactors
Milrinone is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure
These orders are from international government tenders in South Africa, Tanzania, and Kenya, as well as from international agencies WHO/UNFPA, NGOs like MSI and PSI
Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol
Subscribe To Our Newsletter & Stay Updated